Benefit of Atrasentan in Men with Hormone Refractory Prostate Cancer Metastatic to Bone
| Autor: | Jeffrey D. Isaacson, A. R. Allen, A. Lipton, D. J. Sleep, S. M. Hulting |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty animal structures Time to progression business.industry organic chemicals Atrasentan complex mixtures Hormone refractory prostate cancer Internal medicine embryonic structures polycyclic compounds medicine In patient Bone Alkaline Phosphatase business medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 22:4687-4687 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2004.22.90140.4687 |
| Popis: | 4687 Background: Bone alkaline phosphatase (BAP) predicts time to progression (TTP) and survival in patients with hormone refractory prostate cancer (HRPC). We tested 2 hypotheses: a) BAP at baseli... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|